KKR Sinks Its Teeth Into Henry Schein

Henry Schein gets $250 million investment from private equity firm KKR
Private equity firm KKR & Co. Inc. has invested $250 million in Henry Schein Inc., Long Island’s largest publicly traded company by revenue, the Melville-based company announced Wednesday.
KKR Sinks Its Teeth Into Henry Schein With Additional Investment And Board Seats: Details
Henry Schein, Inc. (NASDAQ:HSIC) shares are trading higher on Wednesday. The medical and dental supplies distributor disclosed a strategic investment of an additional $250 million from funds affiliated with KKR & Co.
KKR To Become 12% Shareholder In Henry Schein With Additional $250M Investment: Retail Cheers The Deal
Shares of KKR & Co Inc (KKR) and Henry Schein drew retail attention on Wednesday after it was revealed that the private equity giant will become a 12% common shareholder in the healthcare solutions firm.
KKR Takes Strategic Stake in Medical Supplier Henry Schein
KKR & Co. has taken a 12% stake in Henry Schein Inc. and will work with the company to improve operations at the world’s largest distributor of medical products to office-based dentists and doctors.
Henry Schein announces KKR investment, prelim. Q4 sales (update)
Henry Schein (HSIC) stock in focus as KKR (KKR) builds stake and the company posts its preliminary Q4 2024 financials. Read more here.
Hold Rating on Henry Schein Amid KKR Investment and Market Uncertainties
In a report released on January 29, Michael Cherny from Leerink Partners reiterated a Hold rating on Henry Schein (HSIC – Research Report),
Henry Schein gets a major private equity investment
Henry Schein announced today that private equity firm KKR is investing $250 million in the medical products manufacturer and distributor.
KKR Builds Stake in Henry Schein, Reaches Deal for Board Seats, WSJ Reports
(Reuters) - Private-equity firm KKR has taken a large stake in Henry Schein and plans to work with the distributor of healthcare products to improve its operations, the Wall Street Journal reported on Wednesday citing people familiar with the matter.
Strategic Investment and Growth Potential Drive Buy Rating for Henry Schein Despite Underwhelming Guidance
Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz from
KKR builds stake in Henry Schein, reaches deal to add board seats
Private equity firm KKR has taken a large stake in Henry Schein and reached a deal to add members to the company's board, the ...
Henry Schein price target raised to $90 from $82 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Henry Schein (HSIC) to $90 from $82 and keeps an Outperform rating on the ...